Fecal Excretion of Calprotectin in Colorectal Cancer Relationship to Tumor Characteristics

Kristinsson, Jon; Armbruster, Christine; Ugstad, M; Kriwanek, S.; Nygaard, K; Tøn, Hege; Fuglerud, P.

doi:10.1080/003655201750065979

Cited by 40 publications

(39 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since carcinoma cells do not synthesize calprotectin, this normal reading suggests that an exudative response had not been provoked. Nevertheless, the sensitivity and specificity of calprotectin in colorectal carcinoma were similar to those in previous reports [10,16,17]. The levels of calprotectin in patients who had colonic polyps or adenomas were within the normal range, presumably a reflection of the limited inflammatory response these polyps were producing within the colonic mucosa.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Faecal calprotectin: a marker of inflammation throughout the intestinal tract

Summerton¹,

Longlands

Wiener

et al. 2002

European Journal of Gastroenterology & Hepatology

163

View full text Add to dashboard Cite

Calprotectin levels are elevated in inflammation and cancer but are not helpful in differentiating between these disorders. In our series, calprotectin was not elevated in colonic polyps or adenomata. Calprotectin could be helpful as a screening method in a general gastroenterology population for inflammatory bowel disease and those with carcinoma, as well as assessing and monitoring disease activity in inflammatory bowel disease.

show abstract

Section: Discussionsupporting

confidence: 83%

“…As in previous reports [14][15][16], there was no significant difference according to colonic site. One patient with ascending carcinoma colon had a normal level.…”

Section: Discussionsupporting

confidence: 59%

Faecal calprotectin: a marker of inflammation throughout the intestinal tract

Summerton¹,

Longlands

Wiener

et al. 2002

European Journal of Gastroenterology & Hepatology

163

View full text Add to dashboard Cite

show abstract

“…In contrast to previous studies [6], the difference between the diagnostic groups in the present study did not reach statistical significance. The median CPT value of 13 mg/l in relatives with CRC is lower than the value of 50 mg/l found in patients with already diagnosed CRC [6, 7, 10, 25, 26]. Possible explanations for this low value could either be bias because of the limited number of patients with CRC or that all the subjects with carcinoma were asymptomatic, in contrast to patients with previously known CRC in earlier studies.…”

Section: Discussioncontrasting

confidence: 49%

Screening of First Degree Relatives of Patients Operated for Colorectal Cancer: Evaluation of Fecal Calprotectin vs. Hemoccult II

Kristinsson¹,

Nygaard²,

Aadland

et al. 2001

Digestion

Self Cite

View full text Add to dashboard Cite

Fecal calprotectin (CPT) is elevated in the majority of patients with known colorectal cancer (CRC), but the specificity is not clarified. Aim: To evaluate if a CPT test (PhiCal ELISA) was more sensitive than Hemoccult II test in detecting colorectal neoplasia, and to obtain reference values in subjects with normal colonoscopy. To evaluate a possible relation between number and extent of dysplasia of adenomas in first degree relatives of patients with CRC and the stage of the carcinoma in the index casus. Further to study the prevalence of CRC and adenomas in the first degree relatives of patients operated for CRC. Method: In a multicenter study, 253 first degree relatives of patients with CRC, aged 50–75 years (mean age 60 years) underwent colonoscopy after having delivered stool samples and three Hemoccult II slides. Results: In 237 first degree relatives from 148 patients with CRC, polyps were found in 118 (50%). Seventy three (31%) had adenomas and 17 had adenomas ≧10 mm. Five had asymptomatic cancers. The specificity of fecal CPT for adenomas at cut off levels ≤10, ≤15 and ≤20 mg/l were 47.4, 59.6 and 71.1%, respectively (max of three samples). The sensitivity at same cut off levels was 56.2, 45.2 and 31.5% and 4/5 of patients with carcinoma had CPT values >15 mg/l. The sensitivity of Hemoccult II for adenomas was 8%, and 4/5 of patients with carcinoma had negative Hemoccult II. The specificity for adenomas was 95%. Conclusion: Fecal CPT test was more sensitive than Hemoccult II in detecting colorectal neoplasia but the specificity was lower. In a high risk group like first degree relatives of patients with CRC, there are good reasons to consider fecal CPT as a first test in selecting patients for endoscopy.

show abstract

“…17 Despite several advantages of calprotectin as a stool maker, fecal calprotectin finally revealed its critical pitfall in differentiating between inflammatory bowel diseases and cancer. 18,19 Furthermore, specificity is too low for screening of colonic polyps …”

Section: Discussionmentioning

confidence: 99%